BTK and B-cell non-Hodgkin lymphoma: While there is an inherent need for trials to expand and include patients with other types of B cell lymphomas, the discovery of additional scaffolding functions for BTK in addition to novel therapeutics targeting these functions will offer new options for clinicians treating patients with malignancies relapsed and refractory to current BTK inhibitors.